EG 427French targeted DNA gene therapy specialist EG427 has closed a €27m Series B financing co-led by VC investor Andera Partners and BPI France to initiate Phase I testing of a Herpes Simplex Virus 1 (nrHSV-1) vector that specifically targets type C neurons to suppress dysfunctions of the bladder in people with spinal injury.
Tag Archive for: US
Ovid Therapeutics - Jeremy LevinBy Jeremy Levin, D.Phil, MB BChir
In a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.